Insider Trends: Insider Sales Extend 90-Day Trend at Veracyte
4:56PM ET 1/15/2020 MT NewswiresOn Jan 14, 2020, Director, Evan Jones, executed a sale of 5,000 shares in Veracyte (VCYT) for $142,521. After the Form 4 filing with the SEC, Jones...
Quotes Snapshot > VCYT
Veracyte Inc VCYT:NASDAQ
Last Price$30.15NASDAQ Previous Close - Last Trade as of 3:59PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$30.15 (4)
Ask (Size)$35.35 (1)
Day Low / HighN/A - N/A
Volume345.0 K
Read more news Recent News
Veracyte, AstraZeneca's Acerta Pharma Pursue Collaboration
8:48AM ET 1/08/2020 MT NewswiresVeracyte (VCYT) said pre-market Wednesday that it has entered into a multi-year collaboration with Acerta Pharma, the hematology research and development...
Insider Trends: Insider Prolongs 90-Day Selling Trend at Veracyte
4:39PM ET 12/18/2019 MT NewswiresEvan Jones, Director, reported a sale of 15,000 shares in Veracyte (VCYT) on Dec 17, 2019, for $438,866. Following the Form 4 filing with the SEC, Jones...
Insider Trends: Insider Sale Eases Back 90-Day Buy Trend at Veracyte
4:21PM ET 12/09/2019 MT NewswiresEvan Jones, Director, on Dec 05, 2019, sold 5,951 shares in Veracyte (VCYT) for $178,558. Jones, subsequent to the transactions disclosed in the SEC Form...
View all Commentary and Analysis
Veracyte: Adding Another Big Pharma Partner Backs Bullish Outlook
8:01PM ET 1/14/2020 Seeking AlphaV&M Premium Portfolio: 2019 End Of Year Report Card Through Week 49
5:29AM ET 12/10/2019 Seeking AlphaVeracyte, Inc. 2019 Q3 - Results - Earnings Call Presentation
12:37AM ET 10/23/2019 Seeking AlphaVeracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2019 Earnings Call Transcript
12:36AM ET 10/23/2019 Seeking AlphaCompany Profile
Business DescriptionVeracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 6000 Shoreline Court South San Francisco, California 94080 |
| Phone | +1.650.243.6300 |
| Number of Employees | 270 |
| Recent SEC Filing | 01/15/2020 4 |
| Chairman & Chief Executive Officer | Bonnie H. Anderson |
| Chief Operating & Financial Officer | Keith Kennedy |
| Chief Scientific & Medical Officer | Giulia C. Kennedy |
| Chief Information Officer | Ashish Kheterpal |
Company Highlights
| Price Open | $30.48 |
| Previous Close | $30.17 |
| 52 Week Range | $15.82 - 31.18 |
| Market Capitalization | $1.5 B |
| Shares Outstanding | 48.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/24/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.19 |
| Beta vs. S&P 500 | N/A |
| Revenue | $92.0 M |
| Net Profit Margin | -7.08% |
| Return on Equity | -5.33% |
Analyst Ratings as of 07/31/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |